Stop HF

A Phase II Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of JVS-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure

Stop HF [NCT01643590]

Description: This is a randomized, double-blind, placebo controlled Phase II study is designed to assess the safety and efficacy of using JVS-100 to treat heart failure.


Biological: JVS-100 15 mg dose Injection; Biological: Placebo Injection; Biological:JVS-100 30 mg dose injection

Primary Investigator: Chung

Drug/Device Information
Single doses of JVS-100 delivered via endomyocardial injection for ischemic cardiomyopathy
ACL-01110Sk containing Human stromal cell-derived factor 1alpha (SDF-1) coding sequence
Randomized 1:1:1 to receive either placebo, 15 mg or 30 mg of JVS-100
Juventas Therapeutics, Inc.